MobilEye Global Inc vs Merck & Co., Inc. — how do they compare? MobilEye Global Inc trades at $8.76 (market cap $7.54B), while Merck & Co., Inc. trades at $131.79 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 42.7× MobilEye Global Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| MBLY | MRK | |
|---|---|---|
Market Cap | $7.54B | $321.77B |
Sector | Technology | Health |
52-Week High | $15.54 | $131.84 |
52-Week Low | $6.56 | $77.60 |
Enterprise Value | $6.10B | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
Mobileye Global Inc. (MBLY) trades at $8.81, up 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings beats, driven by an R&D grant, though it remains unprofitable with a net income margin of -201.49%. Recent news highlights CEO transition plans and a new supply deal with Stellantis, while analyst consensus is bullish with a $11.40 price target.
The outlook is mixed: raised 2026 guidance and strategic partnerships offer growth potential in autonomous driving, but persistent losses, leadership changes, and high valuation multiples pose significant risks. Investors should weigh the company's technological positioning against its current financial health and execution challenges in a competitive market.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →